Compare BGI & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGI | ABP |
|---|---|---|
| Founded | 1879 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7M | 18.8M |
| IPO Year | 2005 | N/A |
| Metric | BGI | ABP |
|---|---|---|
| Price | $1.04 | $5.87 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.0K | ★ 28.9K |
| Earning Date | 12-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $136,846,182.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 7.45 | ★ 50.00 |
| 52 Week Low | $0.56 | $4.55 |
| 52 Week High | $2.03 | $153.90 |
| Indicator | BGI | ABP |
|---|---|---|
| Relative Strength Index (RSI) | 36.09 | 55.92 |
| Support Level | $1.00 | $5.55 |
| Resistance Level | $1.09 | $6.38 |
| Average True Range (ATR) | 0.05 | 0.54 |
| MACD | -0.01 | -0.26 |
| Stochastic Oscillator | 20.32 | 33.88 |
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.